Healthcare can be a complex sector, and it is one that I long ago decided to outsource to the industry professionals who run closed-end fund Blackrock Health Sciences Trust. But I couldn't resist dipping my toe into the sector when I saw the historically high yield on offer from Medtronic (MDT 0.88%), one of the largest and most diversified medical device makers.
Medtronic (MDT) concluded the recent trading session at $88.98, signifying a +0.85% move from its prior day's close.
Medtronic's Hypertension business is on the brink of a major expansion, driven by its Simplicity blood pressure procedure.
Boston Scientific, Abbott and Medtronic are included in this Analyst Blog.
Medtronic (MDT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Upgraded Medtronic to a ‘Buy' rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth, highlighting significant momentum in its Cardiac Ablation Solutions business. The company's structural heart business, especially the Evolut FX+ TAVR system, is showing strong adoption and competitive advantages over Edwards Lifesciences's SAPIEN TAVR product.
The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Stability is Kenny Polcari's theme when it comes to today's Big 3. He explains why Cola-Cola (KO), Medtronic (MDT) and L3Harris (LHX) are undervalued names with quality.
At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to mitigate any impact of U.S. President Donald Trump's tariff plans, a company executive told Reuters on Tuesday.